Detecting lung infections in breathprints: empty promise or next generation diagnosis of infections

A wide spectrum of diagnostic technologies and tools are used to identify the agents causing infectious diseases [1–3]. It is increasingly recognised that an improved diagnostic tool should evolve into a personalised approach, fully taking into account 1) identification of individuals at risk of developing diseases; 2) interpretation of diagnostic tests; 3) providing prognostic information; and 4) predicting and following the efficacy of therapies [4]. A new noninvasive and potentially inexpensive frontier in the diagnosis of infectious diseases relies on the detection of volatile organic compounds (VOCs), which are organic compounds that have a high vapour pressure in ordinary room-temperature conditions, from exhaled breath [5–8]. A discussion of evidence on the link between breathprints of bacterial lung infections and the immune response http://ow.ly/DgOOb

[1]  A. Alwan.  Global status report on noncommunicable diseases 2010. , 2011 .

[2]  P Tappenden,et al.  Systematic review and economic evaluation of bevacizumab and cetuximab for the treatment of metastatic colorectal cancer. , 2007, Health technology assessment.

[3]  K. Floyd,et al.  Rapid molecular TB diagnosis: evidence, policy-making and global implementation of Xpert®MTB/RIF Weyer, , 2013 .

[4]  Jiangjiang Zhu,et al.  Breathprints of model murine bacterial lung infections are linked with immune response , 2014, European Respiratory Journal.

[5]  Hossam Haick,et al.  Volatile organic compounds of lung cancer and possible biochemical pathways. , 2012, Chemical reviews.

[6]  P. Sansonetti,et al.  Overview of Bacterial Pathogens , 2011 .

[7]  H. Haick,et al.  Detection of lung, breast, colorectal, and prostate cancers from exhaled breath using a single array of nanosensors , 2010, British Journal of Cancer.

[8]  Deborah H Yates,et al.  A breath test for malignant mesothelioma using an electronic nose , 2011, European Respiratory Journal.

[9]  Heather D. Bean,et al.  Secondary electrospray ionization-mass spectrometry (SESI-MS) breathprinting of multiple bacterial lung pathogens, a mouse model study. , 2013, Journal of applied physiology.

[10]  S. Ward,et al.  A systematic review and economic evaluation of statins for the prevention of coronary events. , 2007, Health technology assessment.

[11]  Joshua T. Morgan,et al.  Characterization of Volatile Organic Compounds in Human Leukocyte Antigen Heterologous Expression Systems: a Cell's “Chemical Odor Fingerprint” , 2012, Chembiochem : a European journal of chemical biology.

[12]  H. Haick,et al.  Unique volatolomic signatures of TP53 and KRAS in lung cells , 2014, British Journal of Cancer.

[13]  Hans Weda,et al.  Exhaled breath metabolomics as a noninvasive diagnostic tool for acute respiratory distress syndrome , 2014, European Respiratory Journal.

[14]  H. Haick,et al.  A nanomaterial-based breath test for distinguishing gastric cancer from benign gastric conditions , 2013, British Journal of Cancer.

[15]  Ulrike Tisch,et al.  The scent fingerprint of hepatocarcinoma: in-vitro metastasis prediction with volatile organic compounds (VOCs) , 2012, International journal of nanomedicine.

[16]  Heather D. Bean,et al.  Robust detection of P. aeruginosa and S. aureus acute lung infections by secondary electrospray ionization-mass spectrometry (SESI-MS) breathprinting: from initial infection to clearance , 2013, Journal of breath research.

[17]  D. Klemp,et al.  Volatile organic compounds in the exhaled breath of young patients with cystic fibrosis , 2006, European Respiratory Journal.

[18]  H. Haick,et al.  Assessment of the exhalation kinetics of volatile cancer biomarkers based on their physicochemical properties , 2014, Journal of breath research.

[19]  Z. Borrill,et al.  Exhaled breath condensate biomarkers in COPD , 2008, European Respiratory Journal.

[20]  H. Haick,et al.  Nanomaterial-based sensors for detection of disease by volatile organic compounds. , 2013, Nanomedicine.

[21]  Hossam Haick,et al.  Assessment, origin, and implementation of breath volatile cancer markers. , 2014, Chemical Society reviews.

[22]  N Waugh,et al.  A systematic review of rapid diagnostic tests for the detection of tuberculosis infection. , 2007, Health technology assessment.

[23]  L. Cuevas,et al.  Use of tuberculin skin test, IFN-&ggr; release assays and IFN-&ggr;-induced protein-10 to identify children with TB infection , 2012, European Respiratory Journal.

[24]  A. Sher,et al.  Immunology of Infectious Disease , 2002 .

[25]  H. Haick,et al.  Detecting active pulmonary tuberculosis with a breath test using nanomaterial-based sensors , 2014, European Respiratory Journal.

[26]  Radu Ionescu,et al.  Volatile fingerprints of cancer specific genetic mutations. , 2013, Nanomedicine : nanotechnology, biology, and medicine.

[27]  E Goyder,et al.  A review and critique of modelling in prioritising and designing screening programmes. , 2007, Health technology assessment.

[28]  Charles Auffray,et al.  Application of ’omics technologies to biomarker discovery in inflammatory lung diseases , 2013, European Respiratory Journal.

[29]  Hossam Haick,et al.  Sniffing the unique "odor print" of non-small-cell lung cancer with gold nanoparticles. , 2009, Small.

[30]  Ulrike Tisch,et al.  Classification of lung cancer histology by gold nanoparticle sensors. , 2012, Nanomedicine : nanotechnology, biology, and medicine.

[31]  Sven Rahmann,et al.  Differentiation of chronic obstructive pulmonary disease (COPD) including lung cancer from healthy control group by breath analysis using ion mobility spectrometry , 2010 .

[32]  H. Haick,et al.  Sensors for breath testing: from nanomaterials to comprehensive disease detection. , 2014, Accounts of chemical research.